Abstract With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID‐19) could develop into severe pneumonia, acute respiratory distress syndrome and multi‐organ failure. Remarkably, in addition to the respiratory symptoms, some COVID‐19 patients also suffer from cardiovascular injuries. Dipeptidyl peptidase‐4 (DPP‐4) is a ubiquitous glycoprotein which could act both as a cell membrane‐bound protein and a soluble enzymatic protein after cleavage and release into the circulation. Despite angiotensin‐converting enzyme 2 (ACE2), the recently recognized receptor of SARS‐CoV and SARS‐CoV‐2, which facilitated their entries into the host, DPP‐4 has been identified as the receptor of middle east respiratory syndrome coronavirus (MERS‐CoV). In the current review, we discussed the potential roles of DPP‐4 in COVID‐19 and the possible effects of DPP‐4 inhibitors on cardiovascular system in patients with COVID‐19.
【저자키워드】 COVID‐19, cardiovascular system, DPP‐4 inhibitors, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, ACE2, coronavirus, acute respiratory distress syndrome, cardiovascular system, MERS, severe acute respiratory syndrome Coronavirus, COVID‐19, SARS‐CoV‐2, Protein, outbreak, Patient, Middle East respiratory syndrome Coronavirus, cleavage, glycoprotein, receptor, circulation, severe pneumonia, respiratory, inhibitor, acute respiratory distress, New coronavirus, angiotensin, Healthcare system, respiratory symptoms, respiratory distress, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, enzyme, syndrome, respiratory syndrome coronavirus, Host, Effect, Cell, develop, addition, facilitated, COVID‐19 patient, 【제목키워드】 inhibitor, Effect, COVID‐19 patient,